KURA ONCOLOGY, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
KURA ONCOLOGY, INC. (KURA) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of -$309.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2026-03-05
- KURA ONCOLOGY, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2025 was -$309.00K.
- KURA ONCOLOGY, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was -$585.00K.
- KURA ONCOLOGY, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was -$409.00K.
- KURA ONCOLOGY, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2022 was -$69.00K.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 4 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | -$309.00K 10-K · filed 2026-03-05 | ||
| 2024-12-31 | -$585.00K 10-K · filed 2026-03-05 | $263.00K 10-K · filed 2025-02-28 | |
| 2023-12-31 | -$409.00K 10-K · filed 2026-03-05 | -$332.00K 10-K · filed 2024-02-27 | |
| 2022-12-31 | -$69.00K 10-K · filed 2025-02-28 | ||
| 2021-12-31 | -$496.00K 10-K · filed 2024-02-27 | ||
| 2020-12-31 | -$120.00K 10-K · filed 2023-02-23 | ||
| 2019-12-31 | $199.00K 10-K · filed 2022-02-24 | ||
| 2018-12-31 | -$8.00K 10-K · filed 2021-02-24 | ||
| 2017-12-31 | -$209.00K 10-K · filed 2020-02-25 | ||
| 2016-12-31 | -$112.00K 10-K · filed 2018-03-12 | $50.00K 10-K · filed 2017-03-14 | |
| 2015-12-31 | $29.00K 10-K · filed 2017-03-14 | ||
| 2014-12-31 | $13.00K 10-K · filed 2016-03-17 | -$100.00 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |